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Failure	  of	  the	  surgical	  treatment	  in	  115	  infected	  hip	  arthroplasties-­analysis	  
of	  a	  12-­year	  prosthetic	  joint	  cohort	  study	  (1999-­2010)	  
ABSTRACT	  
Background:	  Infection	  after	  total	  or	  partial	  hip	  arthroplasty	  (HA)	  leads	  to	  significant	  long-­‐term	  morbidity	  and	  high	  healthcare	  cost.	  We	  evaluated	  reasons	  for	  treatment	  failure	  of	  different	  surgical	  modalities	  in	  a	  12-­‐year	  prosthetic	  hip	  joint	  infection	  cohort	  study.	  
Method:	  All	  patients	  hospitalized	  at	  our	  institution	  with	  infected	  HA	  were	  included	  either	  retrospectively	  (1999-­‐2007)	  or	  prospectively	  (2008-­‐2010).	  HA	  infection	  was	  defined	  as	  growth	  of	  the	  same	  microorganism	  in	  ≥2	  tissues	  or	  synovial	  fluid	  culture,	  visible	  purulence,	  sinus	  tract	  or	  acute	  inflammation	  on	  tissue	  histopathology.	  Outcome	  analysis	  was	  performed	  at	  outpatient	  visits,	  followed	  by	  contacting	  patients,	  their	  relatives	  and/or	  treating	  physicians	  afterwards.	  
Results:	  During	  the	  study	  period,	  117	  patients	  with	  infected	  HA	  were	  identified.	  We	  excluded	  2	  patients	  due	  to	  missing	  data.	  The	  average	  age	  was	  69	  years	  (range,	  33-­‐102	  years);	  42%	  were	  female.	  HA	  was	  mainly	  performed	  for	  osteoarthritis	  (n=84),	  followed	  by	  trauma	  (n=22),	  necrosis	  (n=4),	  dysplasia	  (n=2),	  rheumatoid	  arthritis	  (n=1),	  osteosarcoma	  (n=1)	  and	  tuberculosis	  (n=1).	  28	  infections	  occurred	  early	  (≤3	  months),	  25	  delayed	  (3-­‐24	  months)	  and	  63	  late	  (≥24	  months	  after	  surgery).	  Infected	  HA	  were	  treated	  with	  	  (i)	  two-­‐stage	  exchange	  in	  59	  patients	  (51%,	  cure	  rate:	  93%),	  (ii)	  one-­‐stage	  exchange	  in	  5	  (4.3%,	  cure	  rate:	  100%),	  (iii)	  debridement	  with	  change	  of	  mobile	  parts	  in	  18	  (17%,	  cure	  rate:	  83%),	  (iv)	  debridement	  without	  change	  of	  mobile	  parts	  in	  17	  (14%,	  cure	  rate	  :	  53%	  ),	  (v)	  Girdlestone	  in	  13	  (11%,	  cure	  rate:	  100%),	  and	  (vi)	  two-­‐stage	  exchange	  followed	  by	  removal	  in	  3	  (2.6%).	  Patients	  were	  followed	  for	  an	  average	  of	  3.9	  years	  (range,	  0.1	  to	  9	  years),	  7	  patients	  died	  unrelated	  to	  the	  infected	  HA.	  15	  patients	  (13%)	  needed	  additional	  operations,	  1	  for	  mechanical	  reasons	  (dislocation	  of	  spacer)	  and	  14	  for	  persistent	  infection:	  11	  treated	  with	  debridement	  and	  retention	  (8	  without	  change;	  and	  3	  with	  change	  of	  mobile	  parts)	  and	  3	  with	  two-­‐stage	  exchange.	  The	  average	  number	  of	  surgery	  was	  2.2	  (range,	  1	  to	  5).	  	  The	  infection	  was	  finally	  eradicated	  in	  all	  patients,	  but	  the	  functional	  outcome	  remained	  unsatisfactory	  in	  20%	  (persistent	  pain	  or	  impaired	  mobility	  due	  to	  spacer	  or	  Girdlestone	  situation).	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  There	  has	  been	  a	  marked	  increase	  in	  the	  number	  of	  total	  hip	  replacements	  undertaken	  during	  the	  last	  few	  decades.	  In	  Switzerland,	  hip	  joint	  arthroplasty	  was	  1.9/1000	  in	  2002	  to	  2.4/1000	  inhabitants	  in	  2008.	  In	  2009	  17,251	  patients	  had	  THA	  2,975	  patients	  had	  hemi-­‐arthroplasty	  in	  Switzerland.	  This	  increase	  is	  also	  accompanied	  by	  a	  rise	  in	  the	  number	  of	  associated	  complications.	  (1).	  Unfortunatelly	  results	  of	  treatment	  after	  infection	  of	  an	  arthroplasty	  vary	  enormously	  and	  the	  rate	  of	  successful	  control	  of	  infection	  by	  revision	  hip	  arthroplasty	  can	  lie	  between	  very	  low	  30%	  but	  go	  up	  to	  80%–100%.	  (2)	  Joint	  arthroplasty	  is	  an	  operation,	  which	  has	  good	  results	  regarding	  pain,	  mobility	  and	  quality	  of	  life.	  This	  is	  especially	  true	  for	  those	  patients	  who	  suffered	  osteoarthritis.	  HA	  infection	  is	  potentially	  very	  dangerous.	  It	  can	  lead	  to	  serious	  illness	  and	  high	  cost	  for	  the	  patients	  and	  the	  population	  (5).	  In	  recent	  years,	  significant	  progresses	  have	  been	  made	  to	  decrease	  the	  rate	  of	  infection	  as	  antimicrobial	  prophylaxis	  and	  laminar	  flow	  operating	  rooms	  have	  been	  introduced.	  The	  rate	  of	  infection	  of	  total	  hip	  prosthesis	  is	  described	  to	  lie	  around	  1-­‐2%	  in	  the	  literature.	  	  (6,7,8)	  Infected	  HA	  are	  classified	  in	  3	  categories;	  early	  (develops	  in	  the	  3	  first	  months	  after	  surgery)	  delayed	  (between	  3	  to	  24	  months	  after	  surgery)	  and	  late	  (after	  24	  months	  after	  surgery)	  (5).	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Early	  infection	  occurs	  within	  the	  first	  3	  months	  after	  surgery	  and	  is	  typically	  associated	  with	  clear,	  unmistakable	  signs	  and	  symptoms	  such	  as	  pain,	  warmth	  and	  redness	  in	  and	  around	  the	  implant.	  Highly	  virulent	  microorganisms	  such	  as	  Staphylococcus	  aureus	  or	  Gram	  negative	  Bacillus	  cause	  this	  type	  of	  infection.	  Delayed	  infection	  occurs	  between	  3	  and	  24	  months	  after	  surgery.	  It	  is	  associated	  with	  subtle	  signs	  and	  symptoms	  such	  as	  persistent	  joint	  pain	  and	  is	  caused	  by	  less	  virulent	  bacteria;	  notably	  Coagulase-­‐negative	  Staphylococcus	  and	  Propionibacterium	  acnes.	  Late	  infection	  is	  generally	  hematogenous:	  the	  bacteria	  frequently	  come	  from	  the	  skin	  and	  the	  urinary	  tract	  and	  are	  highly	  virulent.	  However	  the	  hematogenous	  route	  can	  occur	  at	  all	  time	  (5,8,9).	  The	  most	  common	  microorganisms	  causing	  infected	  prosthesis	  are	  Coagulase-­‐negative	  Staphylococcus	  and	  Staphylococcus	  aureus,	  depending	  on	  the	  study.	  Less	  frequently,	  Streptococcus	  spp,	  Enterococcus,	  Propionibacterium	  acnes	  and	  Gram-­‐negative	  bacteria	  are	  also	  to	  be	  found	  (6,	  9).	  	  One	  of	  the	  main	  characteristics	  of	  these	  microorganisms	  is	  their	  ability	  to	  produce	  a	  biofilm	  that	  conceals	  the	  infection	  from	  the	  immune	  system.	  Bacteria	  living	  in	  this	  biofilm	  enter	  slow	  growing	  states	  that	  make	  them	  difficult	  to	  be	  eradicated	  with	  antibiotic	  therapy.	  Furthermore	  there	  is	  no	  microcirculation	  on	  the	  implant	  that	  can	  allow	  the	  antibiotic	  and	  host	  immune	  system	  to	  reach	  the	  surface	  of	  the	  elements	  of	  the	  artificial	  joint.	  The	  goal	  of	  the	  treatment	  of	  infected	  arthroplasties	  is	  to	  eradicate	  the	  infection	  by	  conserving	  a	  long-­‐term	  pain-­‐free	  functional	  extremity,	  which	  depends	  upon	  eradication	  of	  the	  infection.	  Long-­‐term	  suppressive	  antimicrobial	  therapy	  is	  used	  if	  surgery	  is	  contra-­‐indicated,	  but	  this	  only	  temporarily	  controls	  the	  symptoms	  without	  eradicating	  the	  infection.	  (5)	  To	  successfully	  treat	  an	  infected	  arthroplasty	  both	  surgical	  and	  antibiotic	  treatment	  are	  mandatory	  (5,9).	  The	  algorithm	  published	  by	  Zimmerli	  and	  al	  in	  2004	  (5)	  gives	  an	  excellent	  and	  clear	  treatment	  plan	  concerning	  the	  management	  of	  an	  infected	  prosthetic	  joint.	  	  	  According	  to	  Zimmerli’s	  algorithm,	  the	  treatment	  options	  are	  the	  following	  (5):	  -­‐Debridement	  with	  retention	  for	  infection	  with	  clinical	  symptoms	  for	  less	  than	  3	  weeks,	  a	  stable	  implant,	  good	  condition	  of	  the	  surrounding	  soft	  tissue,	  no	  sinus	  tract	  and	  available	  antimicrobial	  agent	  with	  action	  against	  organisms	  living	  in	  biofilm.	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-­‐	  One-­‐stage	  exchange	  if	  the	  patient	  doesn’t	  fulfill	  the	  above	  criteria	  but	  if	  the	  soft	  tissue	  is	  intact	  or	  only	  slightly	  compromised,	  if	  there	  is	  no	  difficult-­‐to	  –treat	  pathogen	  and	  no	  severe	  co-­‐morbidity.	  	  -­‐	  Two-­‐stage	  exchange	  for	  infections	  with	  compromised	  surrounding	  soft	  tissue.	  A	  short	  interval	  (2-­‐4	  weeks)	  and	  an	  anti-­‐microbial	  impregnated	  bone	  cement	  spacer	  is	  used	  except	  if	  there	  is	  a	  difficult-­‐to-­‐treat	  pathogen	  like	  rifampicin	  resistant	  staphylococcus,	  quinolone	  resistant	  Gram	  negative,	  fungi	  and	  Enterococcus.	  In	  the	  latter	  case	  a	  longer	  interval	  (6-­‐8	  weeks)	  and	  no	  spacer	  are	  used.	  -­‐	  Implant	  removal	  without	  replacement	  or	  joint	  arthrodesis	  are	  reserved	  for	  the	  patients	  with	  severe	  immuno-­‐suppression,	  active	  i.v.	  drug	  abuse	  or	  if	  there	  is	  no	  functional	  improvement	  to	  be	  expected	  after	  the	  operation,	  or	  with	  high	  co-­‐morbidity.	  There	  is	  considerate	  debate	  concerning	  the	  optimal	  treatment	  of	  infected	  hip	  arthroplasties,	  due	  to	  the	  absence	  of	  well-­‐designed	  prospective	  randomized,	  controlled	  trials.	  Therefore,	  in	  this	  present	  retrospective	  and	  prospective	  study	  we	  evaluate	  the	  characteristics	  of	  infected	  THA	  and	  both	  the	  functional	  and	  microbiological	  outcome	  according	  to	  the	  surgical	  and	  antimicrobial	  treatment,	  the	  type	  of	  infection,	  and	  the	  type	  of	  microorganism.	  In	  our	  study,	  we	  focus	  more	  precisely	  on	  the	  failure	  of	  surgical	  and	  antimicrobial	  treatments,	  and	  the	  reasons	  for	  their	  failure.	  In	  this	  study	  we	  also	  look	  at	  whether	  the	  surgical	  treatment	  respects	  Zimmerli’s	  algorithm.	  	  	  
Patients	  and	  methods:	  This	  is	  a	  retrospective	  study	  from	  1997	  to	  2007	  and	  prospectively	  between	  2008	  and	  2010.	  This	  study	  was	  conducted	  on	  all	  patients	  who	  were	  hospitalized	  in	  the	  CHUV	  during	  this	  period	  for	  an	  infected	  HA,	  i.e.	  117	  patients.	  	  We	  analyzed	  the	  electronic	  data	  and	  the	  medical	  charts	  of	  all	  the	  patients	  to	  find:	  the	  first	  implantation,	  the	  time	  of	  hospitalization,	  the	  surgical	  and	  infectious	  therapies,	  signs	  and	  symptoms	  of	  the	  infection,	  radiological	  and	  infectious	  parameters.	  We	  also	  checked	  to	  see	  if	  there	  were	  complications	  during	  hospitalization.	  And	  finally,	  we	  looked	  at	  the	  follow	  –up	  and	  the	  microbial	  and	  functional	  outcomes.	  Outcome	  analysis	  was	  performed	  at	  outpatient	  visits,	  followed	  by	  contacting	  patients,	  their	  relatives	  and/or	  treating	  physicians	  afterwards.	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Criteria	  of	  inclusion/exclusion:	  All	  the	  patients	  who	  were	  hospitalized	  in	  the	  CHUV	  with	  a	  documented	  infected	  HA	  during	  the	  period	  between	  January	  1997	  and	  December	  2010	  were	  included.	  Two	  patients	  were	  excluded	  due	  to	  lack	  of	  data.	  
Definitions:	  
	  
THA	  Infection:	  A	  case	  is	  defined	  as	  a	  HA	  infection	  when	  one	  or	  more	  of	  the	  following	  criteria	  is	  present	  (5):	  
-­‐ Sinus	  tract	  communicating	  with	  the	  joint	  space	  
-­‐ Growth	  in	  tissue	  or	  synovial	  fluid	  cultures	  (low-­‐virulent	  micro-­‐organisms	  required	  two	  specimens	  with	  growth	  of	  the	  same	  micro-­‐organism)	  
-­‐ Visible	  purulence	  at	  implant	  site	  (as	  determined	  by	  the	  surgeon)	  
-­‐ Acute	  inflammation	  on	  tissue	  histopathology	  (as	  determined	  by	  the	  pathologist).	  
-­‐ New:	  Positive	  sonication	  (>50	  CFU/ml)	  or	  calorimetry	  (9)	  
Surgical	  therapy:	  
Debridement	  and	  retention:	  Debridement	  involves	  removal	  of	  the	  hematoma,	  fibrous	  membranes,	  and	  devitalized	  bone	  and	  soft	  tissue.	  The	  mobile	  parts	  can	  be	  changed	  (DC)	  or	  not	  (DN).	  
One	  -­stage	  exchange:	  Includes	  removal	  of	  all	  foreign	  material,	  debridement,	  and	  re-­‐implantation	  of	  a	  new	  prosthesis	  during	  the	  same	  procedure.	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Two-­stage	  exchange	  (short	  2	  weeks	  vs.	  long	  6	  weeks	  interval):	  Implantation	  of	  the	  new	  prosthesis	  is	  delayed	  for	  a	  variable	  period	  of	  time.	  An	  anti-­‐microbial	  impregnated	  bone	  cement	  spacer	  is	  usually	  inserted.	  
Girdlestone:	  involves	  removing	  the	  prosthesis,	  hematoma,	  fibrous	  membranes,	  and	  devitalized	  bone	  and	  soft	  tissue.	  
	  	  	  	  	  	  Outcome	  evaluation	  	  Good	  surgical	  outcome	  is	  defined	  as	  the	  success	  of	  the	  first	  surgical	  approach	  without	  additional	  surgery	  to	  eradicate	  the	  infection.	  	  Good	  microbiological	  outcome	  is	  defined	  as	  the	  eradication	  of	  the	  infection	  at	  final	  follow-­‐up.	  	  Good	  final	  outcome	  is	  defined	  as	  a	  painless,	  functional	  hip	  joint	  
Results:	  
	  
Demographic	  data:	  A	  total	  of	  117	  patients	  were	  identified,	  of	  whom	  2	  were	  excluded	  due	  to	  lack	  of	  data.	  Table	  1	  summarizes	  the	  demographic	  data.	  The	  average	  age	  is	  69	  years;	  42%	  of	  the	  patients	  were	  female.	  The	  average	  time	  follow-­‐up	  after	  the	  first	  surgery	  for	  THA	  was	  46.52	  months.	  
	  
Table	  1:	  demographic	  data	    Number	  of	  patients	  	   115	  Average	  (range),	  years	   69y	  (33y-­‐102y)	  Female	   48	  (41.7%)	  Average	  follow-­‐up	  (months)	   46.52	  (1.4-­‐275,3)	  	  
Characteristic	  of	  infected	  prosthesis	  Table	  2	  summarizes	  the	  characteristic	  of	  infected	  prosthesis.	  100	  patients	  had	  a	  THA	  and	  15	  had	  a	  hemi-­‐prosthesis.	  The	  main	  reason	  for	  the	  first	  implantation	  was	  osteoarthritis	  (84	  cases,	  73.04%),	  traumatic	  (22	  cases,	  19.13%),	  rheumatic	  arthritis	  (1	  case,	  0.86%),	  necrosis	  of	  femoral	  head	  (3	  cases,	  2.58%),	  osteosarcoma	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(1	  case,	  0.86%),	  tuberculosis	  (1	  case,	  0.86%),	  hip	  dysplasia	  (	  2	  cases,	  1.72%).	  In	  28	  cases	  (24.34%)we	  found	  early	  infection,	  delayed	  infection	  was	  proven	  in	  25	  cases	  (21.34%)	  and	  late	  infection	  was	  present	  in	  63	  cases	  (54.13%).	  
Table	  2:	  Characteristics	  of	  infected	  prosthesis:	  TYPE	  OF	  PROSTHESIS	  
-­‐ THA	  
-­‐ HEMI-­‐	  HA	  	  
	  100	  15	  Reason	  of	  arthroplasty	  
-­‐ Osteoarthritis	  
-­‐ Traumatic	  
-­‐ Rheumatid	  arthritis	  
-­‐ Osteosarcoma	  
-­‐ Necrosis	  of	  the	  hip	  head	  
-­‐ Hip	  dysplasia	  
-­‐ Tuberculosis	  	  	  	  
	  84	  (73.04%)	  22	  (19.13%)	  1	  (0.86%)	  1	  (0.86%)	  2	  (1.72%)	  2	  (1.72%)	  1	  (0.86%)	  Type	  of	  infection	  
-­‐ early	  (	  3months)	  
-­‐ delayed	  (3-­‐24	  months)	  
-­‐ late	  (24	  months)	  
	  28	  (24.34%)	  25	  (21.73%)	  63	  (54.78%)	  
	  
Surgical	  Procedure:	  In	  59	  cases	  (51.3%)	  there	  was	  a	  two-­‐stage	  exchange	  (2S),	  in	  this	  type	  of	  surgery	  there	  were	  4	  re-­‐operations	  (6.77%).	  5	  patients	  (4.34%)	  had	  a	  one-­‐	  stage	  exchange	  (1S).	  In	  the	  debridement	  group,	  there	  were	  18	  debridements	  with	  change	  of	  the	  mobile	  parts	  (DC)	  (15.65%)	  and	  4	  re-­‐operations	  (16.6%),	  17	  debridements	  with	  no	  change	  (DN)	  (14.78%)	  and	  with	  8	  re-­‐operations	  (47.1%).	  The	  Girdlestone	  procedure	  (R)	  was	  carried	  out	  in	  13	  cases	  (11.30%).	  Finally	  there	  were	  3	  patients	  (2.60%)	  with	  a	  spacer	  followed	  by	  a	  Girdlestone	  procedure(S+R).	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Table	  3:	  Surgical	  Procedure	  	  2S	  (4	  re-­‐operations,	  6.77%)	   	  59	   51.3%	  1S	   5	   4.34%	  DC	  (3	  re-­‐operations,	  16.6%)	   18	   15.65%	  DN	  (8	  re-­‐operations,	  47.1%)	   17	   14.78%	  R	   13	   11.3%	  S+R	   3	   2.6%	  
	  
Microbiology:	  The	  pre-­‐operative	  microbiology	  was	  positive	  in	  44	  cases	  (38.20%),	  was	  negative	  in	  32	  patients	  (27.8%)	  and	  not	  done	  in	  39	  cases	  (33.9%).	  78	  patients	  (67.82%)	  had	  positive	  per-­‐operative	  microbiology.	  In	  37	  cases	  (32.17%),	  no	  pathogen	  was	  found.	  Sonication	  was	  done	  on	  only	  21	  patients,	  7	  were	  sterile	  and	  14	  were	  positive.	  Both	  microbiology	  (per-­‐operative	  and	  pre-­‐operative)	  were	  positive	  in	  25	  patients	  (21.73%),	  the	  per-­‐operative	  microbiology	  was	  positive	  alone	  in	  55	  cases	  (47.82%),	  positive	  only	  in	  pre-­‐operative	  in	  19	  people	  (16.52%).	  And	  both	  negative	  in	  16	  cases	  (13.91%).	  Tables	  4	  and	  5	  explain	  the	  details	  of	  the	  microbiology.	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Table	  4:	  Microbiology:	  
	  	  Pre-­‐operative	  microbiology	  
• positive	  
• sterile	  
• not	  done	  
	  44	  32	  39	  
	  38.2%	  27.8%	  22.9%	  Per-­‐operative	  microbiology	  
• positive	  
• sterile	  
	  78	  37	  
	  
	  67.8%	  32.2%	  
Sonication	  
• not	  done	  
• positive	  
• sterile	  
	  94	  14	  7	  
	  81.7%	  12.2%	  6.1%	  
	  
Table	  5:	  Microbiology	  	  Both	  positive	   22	   21.7%	  Only	  pre-­‐operative	   19	   16.5%	  Only	  per-­‐operative	   55	   47.8%	  Both	  negative	   16	   13.9%	  	  In	  65	  cases	  (83.2%)	  a	  single	  pathogen	  was	  discovered	  from	  the	  per-­‐operative	  microbiology	  (bone,	  soft	  tissue,	  prosthesis	  and/or	  synovial	  fluid),	  and	  13	  (16.8%)	  poly-­‐microbial	  infections	  were	  identified.	  Table	  6	  summarizes	  which	  pathogens	  were	  discovered	  in	  the	  per-­‐operative	  microbiology.	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Table	  6:	  Per-­operative	  microbiology:	  Staphylococcus	  aureus	   16	   21%	  MRSA	   6	   7.8%	  Coagulase-­‐negative	  Staphylococcus	   17	   22%	  MRSE	   7	   9.09%	  Enterococcus	  spp(1)	   3	   3.89%	  Streptococcus	  spp(2)	   5	   6.49%	  Propionibacterium	  spp(3)	   4	   5.20%	  Gram	  negative(4)	   4	   5.20%	  Polymicrobial(5)	   13	   16.80%	  Others	  gram	  positive(6)	   2	   2.60%	  Candida	   1	   1.29%	  (1)	  2	  were	  described	  as	  enterococcus	  spp	  and	  1	  enterococcus	  faecalis,	  (2)	  streptococcus	  sanguinis,	  streptococcus	  oralis,	  streptococcus	  agalactiae,	  streptococcus	  mitis,	  ß-­‐hemolytic	  streptococcus	  (C	  group),	  (4)	  2	  were	  Echerichia	  Coli,	  one	  Pseudomonas	  aeruginosa,	  one	  Citrobacter	  koseri	  (5):	  klebesiella	  pneumoniae+peptostreptococcus,	  Eschericha	  Coli+enterococcus	  spp,	  enterococcus	  spp+	  coagulase	  negative	  staphylococcus,	  Coagulase negative staphylococcus: epidermidis+hominis+ E. Coli+ 
propionibacterium acne, Propionibacterium acnes+staphylococcus aureus, Staphylococcus 
aureus+Enterococcus spp, Staphylococcus capitis+Staphylococcus auricularis,+staphyloccus 
simulans, Staphylococcus capitis+staphylococcus hominis,  coagulase negative staphylococcus+ 
propionibacterium acnes, Staphylococcus epidermidis+MRSE, staphylococcus 
haemolyticus+staphylococcus caprae, peptostreptococcus magnus+staphylococcus epidermidis, 
Streptococcus Dysgalaticae+Pseudomonas aeruginosa+staphylococcus aureus (6) Bacillus Cereus, 
Peptostrepococcus magnus	  
Treatment	  	  For	  59	  patients	  (51.3%)	  an	  initial	  2-­‐stage	  exchange	  surgical	  strategy	  was	  pursued	  with	  a	  fairly	  high	  success	  rate.	  Only	  4	  patients	  (6.77%)	  had	  to	  be	  re-­‐operated:	  1	  for	  mechanical	  problems	  (dislocation	  of	  the	  spacer)	  and	  3	  (5.08%)	  for	  infectious	  disorder	  (MRSA,	  S.	  aureus,	  poly-­‐microbial	  infection).	  For	  2	  of	  these	  3	  cases	  of	  infection,	  the	  surgical	  option	  chosen	  was	  replacement	  of	  the	  spacer	  while	  the	  3rd	  patient	  underwent	  a	  2-­‐stage	  exchange	  operation	  for	  the	  second	  time.	  	  1-­‐stage	  exchange	  was	  the	  surgical	  strategy	  chosen	  for	  5	  patients	  (4.34%).	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For	  18	  patients	  (15.65%)	  the	  surgical	  strategy	  pursued	  was	  debridement	  with	  change	  of	  the	  mobile	  part.	  In	  this	  group,	  3	  patients	  (16.66%)	  had	  persistant	  infection	  (MRSA,	  P.	  aeruginosa,	  polymicrobial	  infection).	  All	  3	  had	  to	  undergo	  repeated	  surgery.	  The	  surgical	  strategy	  differed	  in	  each	  of	  these	  3	  cases:	  for	  1	  patient	  a	  Girdlestone	  procedure	  was	  employed;	  for	  1	  a	  2-­‐stage	  exchange	  was	  performed;	  the	  third	  patient	  first	  had	  an	  operation	  for	  a	  spacer,	  which	  was	  followed	  by	  a	  Girdlestone	  procedure.	  	  For	  17	  patients	  (14.78%)	  the	  surgical	  strategy	  pursued	  was	  debridement	  with	  no	  change	  of	  mobile	  parts.	  There	  was	  a	  high	  failure	  rate	  due	  to	  persistent	  infection:	  8	  patients	  (47.1%)	  had	  to	  be	  re-­‐operated.	  2-­‐stage	  exchange	  was	  the	  surgical	  strategy	  pursued	  for	  the	  majority	  of	  these	  cases	  (5	  patients,	  62.5%)	  Girdlestone	  procedure	  was	  the	  surgical	  procedure	  opted	  for	  in	  2	  patients	  (25%).	  Two	  further	  surgical	  procedures	  were	  decided	  on	  for	  the	  final	  patient	  of	  this	  group:	  first	  two	  spacers,	  then	  Girdlestone	  (MRSA’s	  infection)	  20	  patients	  had	  a	  Girdlestone	  procedure	  but	  only	  13	  as	  first	  surgical	  procedure,	  3	  had	  spacers	  and	  then	  a	  Girdlestone	  and	  4	  had	  another	  surgical	  procedure	  as	  first	  procedure	  such	  as	  debridement	  without	  change	  of	  mobile	  parts.	  
	  
Outcome	  The	  mean	  time	  of	  follow-­‐up	  after	  the	  first	  surgery	  for	  the	  THA	  infection	  was	  46.52	  months	  (range	  1.4-­‐275.3).	  During	  this	  time,	  it	  averred	  that	  the	  mean	  surgery	  rate	  required	  was	  2.19	  (range	  1-­‐5	  surgeries).	  It	  may	  be	  noted	  that	  two	  patients	  died	  during	  their	  hospitalization	  but	  not	  from	  THA	  infection.	  	  The	  overall	  final	  outcome	  can	  be	  considered	  fair	  to	  good	  with	  a	  success	  rate	  of	  	  82.6%.	  Successful	  eradication	  of	  the	  microbiological	  infection	  by	  means	  of	  the	  various	  elected	  surgical	  procedures	  was	  virtually	  excellent:	  98%	  –given	  that	  two	  patients	  died	  of	  other,	  non-­‐related	  causes	  during	  the	  follow-­‐up	  period.	  	  100	  episodes	  of	  HA	  infections	  (85.47%)	  were	  eradicated	  after	  the	  first	  surgical	  procedure	  option.	  14	  episodes	  of	  recurrent	  infection	  necessitated	  a	  second	  operation.	  One	  case	  encountered	  mechanical	  difficulties,	  which	  required	  further	  surgery.	  However	  after	  all	  the	  secondary	  surgical	  procedures,	  the	  microbial	  outcome	  was	  completely	  satisfactory;	  all	  infection	  was	  eradicated.	  The	  functional	  outcome	  referring	  to	  the	  successful	  surgical	  procedure	  more	  precisely	  the	  prosthesis	  itself	  can	  be	  considered	  fairly	  good	  with	  a	  69.56%	  success	  rate.	  The	  Girdlestone	  procedure	  had	  the	  best	  for	  the	  successful	  eradication	  of	  THA	  infection	  in	  20	  episodes;	  while	  this	  was	  fully	  satisfactory	  re	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microbiology,	  it	  cannot	  be	  considered	  successful	  regarding	  the	  functional	  	  outcome	  due	  to	  the	  resulting	  reduced	  mobility.	  	  	  
	  
Discussion:	  	  An	  infected	  HA	  can	  be	  treated	  by	  different	  surgical	  procedures.	  These	  procedures	  lead	  to	  different	  results	  for	  the	  same	  type	  of	  infection	  and	  the	  same	  microbiology.	  	  This	  study	  shows	  that	  debridement	  without	  change	  of	  mobile	  parts	  is	  the	  least	  appropriate	  surgical	  procedure	  to	  eradicate	  an	  infected	  THA.	  47.1%	  of	  the	  patients	  for	  whom	  this	  surgical	  procedure	  was	  chosen	  required	  further	  surgery.	  	  A	  comparison	  of	  this	  study	  with	  other	  studies	  (11,12,16)	  confirms	  similar	  high,	  or	  indeed	  higher,	  failure	  rates:	  Betch	  et	  al	  in	  Treatment	  of	  Joint	  Prosthesis	  in	  
accordance	  with	  Current	  Recommendations	  Improves	  Outcomes,	  68	  cases	  of	  infected	  prosthesis,	  50%	  failure	  after	  debridement	  without	  change	  of	  mobile	  parts;	  Trebse	  et	  al	  in	  Treatment	  of	  Infected	  Retained	  Implants	  reported	  a	  70%	  failure	  rate	  after	  debridement	  and	  retention	  in	  24	  cohort	  patients.	  Likewise	  Veuthey	  et	  al	  presented	  at	  EBJIS	  2010	  Characteristic	  and	  Outcome	  of	  Knee	  
Prosthetic	  Joint	  Infections	  and	  reported	  a	  93%	  failure	  rate	  after	  debridement	  without	  change	  of	  mobile	  parts.	  (11,12,16	  )	  This	  surgical	  procedure	  (debridement	  without	  change	  of	  mobile	  parts)	  has	  not	  been	  applied	  in	  the	  CHUV	  for	  5	  years	  now.	  (last	  case	  in	  2006).	  There	  was	  a	  good	  eradication	  rate	  of	  THA	  infection	  after	  debridement	  with	  change	  of	  mobile	  parts,	  in	  both	  one-­‐stage	  exchange	  and	  two-­‐stage	  exchange	  procedures.	  The	  failure	  rate	  for	  debridement	  of	  the	  mobile	  parts	  was	  16.6%	  and	  can	  be	  explained	  by	  non-­‐adherence	  to	  Zimmerli’s	  algorithm	  for	  the	  choice	  of	  surgical	  management	  and	  antimicrobial	  treatment	  (6).	  	  One	  case	  of	  failure	  was	  due	  to	  a	  late	  infection;	  two	  others	  were	  early	  infections	  but	  difficult-­‐to-­‐treat	  bacteria	  (Pseudomonas	  aeruginosa,	  polymicrobial	  (enterococcus)	  infection).	  This	  surgical	  procedure	  could	  have	  as	  high	  a	  success	  rate	  as	  one	  or	  two	  stage-­‐exchanges	  if	  the	  cases	  were	  well	  selected,	  i.e	  no	  presence	  of	  difficult-­‐to-­‐treat	  bacteria,	  intact	  soft	  tissues,	  no	  sinus	  tract,	  no	  loosening/stable	  implant,	  early	  infection	  or	  occurrence	  of	  symptoms	  lasting	  for	  less	  than	  3	  weeks	  (9).	  In	  the	  cases	  we	  studied	  that	  resulted	  in	  failure	  the	  above	  criteria	  were	  not	  respected.	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  The	  success	  rate	  of	  one-­‐	  and	  two-­‐stage	  exchanges	  was	  high–above	  90%.	  In	  our	  study	  only	  5	  patients	  had	  one-­‐stage	  exchange	  and	  no	  second	  surgery	  was	  necessary.	  These	  patients	  were	  well	  selected	  (no	  difficult-­‐to-­‐treat	  bacteria,	  intact	  soft	  tissue).	  The	  success	  rate	  of	  this	  surgical	  procedure	  in	  comparative	  studies	  is	  between	  86%	  and	  100%	  (9,13,14).	  A	  similar	  success	  rate	  was	  also	  the	  case	  for	  2-­‐stage	  exchange	  procedures.	  The	  failure	  rate	  was	  low	  (6.8%)	  and	  concerned	  only	  4	  patients:	  one	  suffered	  mechanical	  failure	  (dislocation	  of	  the	  spacer)	  and	  3	  suffered	  from	  persistant	  infections.	  The	  two-­‐stage	  exchange	  is	  the	  surgical	  procedure	  that	  presents	  the	  lowest	  failure	  risk	  factor,	  particularly	  for	  late	  infection	  and	  difficult-­‐to-­‐treat	  bacteria.	  In	  our	  study,	  the	  intervening	  weeks	  between	  introduction	  of	  the	  spacer	  and	  reimplantation	  of	  a	  new	  prosthesis	  in	  the	  two-­‐stage	  exchange	  procedure	  can	  be	  divided	  into	  two	  groups:	  the	  short	  interval	  group	  (2-­‐4	  weeks)	  and	  the	  long	  interval	  group	  (4	  weeks	  and	  more).	  The	  short	  interval	  group	  concerned	  a	  minority	  of	  patients:	  8	  patients	  (13.5%);	  the	  majority,	  51	  patients	  (86%),	  belonged	  to	  the	  long	  interval	  group.	  The	  advantages	  of	  a	  short	  interval	  are	  fewer	  complications	  due	  to	  bed	  rest	  and	  hospitalization,	  reduction	  of	  costs	  and	  shorter-­‐term	  recovery	  than	  the	  long	  interval	  group.	  However,	  regarding	  short	  interval	  procedures,	  successful	  treatment	  depends	  on	  both	  knowledge	  of	  the	  bacteria,	  and	  its	  belonging	  to	  a	  not-­‐difficult-­‐to-­‐treat	  microorganism.	  Furthermore,	  the	  bacteria	  must	  also	  be	  sensitive	  to	  rifampicin.	  If	  all	  these	  criteria	  are	  present,	  the	  success	  rate	  is	  similar	  to	  the	  long	  interval	  group,	  indeed	  it	  may	  even	  be	  considered	  better	  given	  the	  advantages	  of	  the	  short	  interval	  procedure.	  The	  8	  patients	  in	  the	  short	  interval	  case	  studies	  experienced	  the	  same	  outcome	  as	  the	  long	  interval	  group	  and	  none	  of	  them	  had	  to	  be	  re-­‐operated.	  	  	  	  	  	  The	  success	  rate	  for	  two-­‐stage	  exchange	  was	  93.2%.	  Unfortunately,	  this	  procedure	  involves	  multiple	  surgeries	  and	  can	  lead	  to	  bad	  functional	  mobility	  by	  reducing	  the	  mobility	  of	  the	  joint	  (6,9,15).	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The	  Girdlestone	  procedure	  is	  the	  best	  surgical	  procedure	  for	  eradication	  of	  infection,	  but	  comes	  with	  a	  poor	  functional	  outcome	  since	  the	  patient	  no	  longer	  has	  a	  joint	  prosthesis.	  This	  surgical	  procedure	  is	  used	  only	  in	  patients	  who	  have	  high	  co-­‐morbidities	  such	  as	  severe	  immuno-­‐suppression,	  extensive	  damage	  of	  the	  soft	  tissue,	  active	  iv-­‐drug	  abuse	  or	  when	  a	  re-­‐implantation	  will	  not	  improve	  the	  functional	  outcome	  (6,9).	  In	  our	  study,	  this	  surgical	  procedure	  was	  elected	  as	  the	  best	  option	  for	  20	  patients.	  For	  13	  it	  was	  selected	  as	  the	  first	  treatment;	  3	  patients	  had	  a	  spacer	  followed	  by	  a	  Girdlestone;	  4	  had	  a	  Girdlestone	  as	  final	  treatment,	  i.e.	  the	  Girdlestone	  procedure	  was	  preceded	  by	  another	  surgical	  procedure,	  for	  example	  one	  patient	  had	  a	  debridement	  without	  change	  of	  mobile	  parts	  but	  as	  the	  infection	  was	  not	  eradicated,	  had	  to	  be	  re-­‐operated.	  The	  infection	  was	  eradicated	  in	  all	  of	  the	  patients	  treated	  with	  a	  Girdlestone.	  However,	  removal	  of	  the	  prosthesis	  impairs	  mobility	  and	  motion.	  Hence	  the	  poor	  functional	  outcome	  results	  for	  this	  surgical	  procedure	  (69%)	  in	  our	  study.	  	  
	  
Conclusion:	  	  Overall	  our	  study	  demonstrates	  the	  fact	  that	  when	  selecting	  the	  optimum	  surgical	  procedure,	  the	  type	  of	  infection,	  the	  type	  of	  bacteria	  found,	  the	  condition	  of	  the	  soft	  tissue	  and	  the	  presence	  of	  sinus	  tract	  has	  to	  be	  taken	  into	  consideration,	  and	  the	  implant	  stability	  needs	  to	  be	  evaluated.	  	  Debridement	  with	  no	  change	  of	  mobile	  parts	  is	  the	  least	  appropriate	  surgical	  procedure	  and	  should	  not	  be	  used	  any	  more.	  	  Overall	  treatment	  success	  rate	  of	  debridement	  with	  change	  of	  mobile	  parts	  and	  the	  one-­‐stage	  exchange	  depends	  on	  patients	  being	  well-­‐selected.	  This	  means	  in	  acute	  situations	  (symptoms	  ≤3weeks)	  with	  no	  difficult-­‐to-­‐treat	  bacteria,	  no	  soft	  tissue	  damage,	  no	  fistula	  and	  no	  loosening.	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  The	  two-­‐stage	  exchange	  is	  the	  safest	  surgical	  procedure	  for	  complicated	  situations.	  The	  discussion	  regarding	  short	  and	  long	  interval	  re-­‐implantation	  is	  ongoing.	  	  Given	  the	  results	  of	  our	  study,	  we	  would	  tend	  to	  recommend	  short	  interval	  when	  the	  required	  conditions	  are	  fulfilled.	  Further	  studies	  focusing	  on	  the	  re-­‐implantation	  interval	  time	  should	  provide	  additional	  data	  and	  help	  us	  make	  a	  better	  decisional	  algorithm.	  Finally,	  poor	  selection	  of	  patients	  and	  non-­‐adherence	  to	  Zimmerli’s	  algorithm	  lead	  to	  failure	  of	  the	  treatment.	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